Drugs / EuBone
EuBone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05402852 | Jun → Oct 2022 | postmenopausal osteoporosis | Shandong University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EuBone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05402852 ↗ |
| Known as | EuBone capsule | “The aim of this study is to evaluate the effectiveness and safety of EuBone® capsules in slowing bone loss, preventing bone loss, and improving quality of life compared with...” NCT05402852 ↗ |
| Known as | EuBone Capsules | “The aim of this study is to evaluate the effectiveness and safety of EuBone® capsules in slowing bone loss, preventing bone loss, and improving quality of life compared with...” NCT05402852 ↗ |